Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

534

Participants

Timeline

Start Date

August 15, 2019

Primary Completion Date

December 3, 2020

Study Completion Date

March 2, 2021

Conditions
Eosinophilic AsthmaAsthma
Interventions
DRUG

Dexpramipexole

dexpramipexole twice daily oral dosing for up to 12 weeks

DRUG

Placebo

placebo twice daily oral dosing for up to 12 weeks

Trial Locations (36)

11042

Research Site, New Hyde Park

14830

Research Site, Corning

15205

Research Site, Pittsburgh

27103

Research Site, Winston-Salem

27607

Research Site, Raleigh

29406

Research Site, North Charleston

29621

Research Site, Anderson

30046

Research Site, Lawrenceville

30680

Research Site, Winder

32117

Research Site, Daytona Beach

32803

Research Site, Orlando

33186

Research Site, Miami

33612

Research Site, Tampa

33634

Research Site, Tampa

43016

Research Site, Dublin

43235

Research Site, Columbus

45231

Research Site, Cincinnati

45242

Research Site, Cincinnati

48336

Research Site, Farmington Hills

55441

Research site, Plymouth

63110

Research Site, St Louis

63141

Research Site, St Louis

73034

Research Site, Edmond

75013

Research Site, Allen

75240

Research Site, Dallas

78006

Research Site, Boerne

79902

Research Site, El Paso

80230

Research Site, Denver

83706

Research Site, Boise

89119

Research Site, Las Vegas

90048

Research Site, Los Angeles

92683

Research Site, Westminster

92691

Research Site, Mission Viejo

97202

Research Site, Portland

97504

Research Site, Medford

08901

Research Site, New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Knopp Biosciences

INDUSTRY